Edition:
United States

Merck & Co Inc (MRK)

MRK on New York Consolidated

61.70USD
23 Jan 2018
Change (% chg)

-- (--)
Prev Close
$61.70
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
11,710,316
52-wk High
$66.80
52-wk Low
$53.63

Latest Key Developments (Source: Significant Developments)

Neon Therapeutics To Collaborate with Merk on Clinical Trial
Thursday, 7 Dec 2017 07:00am EST 

Dec 7 (Reuters) - Merck & Co Inc ::NEON THERAPEUTICS ANNOUNCES CLINICAL TRIAL COLLABORATION WITH MERCK.NEON THERAPEUTICS - ENTERED CLINICAL TRIAL COLLABORATION WITH MERCK TO EVALUATE CO'S NEOANTIGEN VACCINE, NEO-PV-01, IN COMBINATION WITH MERCK'S KEYTRUDA.NEON THERAPEUTICS SAYS COLLABORATION AGREEMENT IS BETWEEN CO AND MERCK, THROUGH A SUBSIDIARY; ADDITIONAL DETAILS WERE NOT DISCLOSED..NEON THERAPEUTICS - CO, MERCK TO WORK ON PHASE 1B TRIAL EXAMINING SAFETY, PRELIMINARY EFFICACY OF NEO-PV-01 COMBINED WITH KEYTRUDA, AMONG OTHERS.  Full Article

Merck's Mavenclad (Cladribine Tablets) Approved For Relapsing-Remitting Multiple Sclerosis In Canada
Monday, 4 Dec 2017 03:09am EST 

Merck & Co Inc ::MERCK'S MAVENCLAD (CLADRIBINE TABLETS) APPROVED FOR RELAPSING-REMITTING MULTIPLE SCLEROSIS IN CANADA.  Full Article

Merck Announces $10 Billion Share Repurchase Authorization
Tuesday, 28 Nov 2017 02:33pm EST 

Nov 28 (Reuters) - Merck & Co Inc ::MERCK ANNOUNCES INCREASED QUARTERLY DIVIDEND AND $10 BILLION SHARE REPURCHASE AUTHORIZATION.MERCK & CO INC - AUTHORIZED AN ADDITIONAL $10 BILLION OF TREASURY STOCK PURCHASES WITH NO TIME LIMIT FOR COMPLETION​.MERCK - INCREASED CO'S QTRLY DIVIDEND TO $0.48/OUTSTANDING SHARE OF CO'S COMMON STOCK, UP $0.01 FROM $0.47 PER OUTSTANDING SHARE PAID LAST QUARTER.  Full Article

Cue Biopharma announces collaboration with Merck
Thursday, 16 Nov 2017 08:00am EST 

Nov 16 (Reuters) - Cue Biopharma:‍Cue Biopharma says a strategic research collaboration and license agreement with Merck.Cue Biologics platform will be leveraged to develop biologics engineered to selectively modulate disease-relevant T cell subsets​.Says specific financial arrangements are not being disclosed​.Says will receive an up-front payment​.Eligible to earn up to $374 million in research, regulatory & commercial milestone payments in addition to tiered royalties on sales​.  Full Article

Merck reports 6.5 pct passive stake in Spero Therapeutics as of Nov 6
Wednesday, 15 Nov 2017 04:52pm EST 

Nov 15 (Reuters) - Merck & Co Inc :Merck & Co reports 6.5 percent passive stake in Spero Therapeutics Inc as of Nov 6 - SEC Filing​.  Full Article

Merck reports final results of any and all tender offers
Tuesday, 14 Nov 2017 06:55am EST 

Nov 14 (Reuters) - Merck & Co Inc ::Merck announces final results of any and all tender offers.Merck & Co Inc - ‍offers expired at 5:00 p.m., New York City time, on Nov. 13, 2017​.Merck - amount of notes tendered & accepted for purchase was about $584.7 million, exclusive of notes tendered pursuant to guaranteed delivery procedures​.  Full Article

Merck announces pricing of any and all tender offers
Monday, 13 Nov 2017 02:00pm EST 

Nov 13 (Reuters) - Merck & Co Inc ::Merck announces pricing of any and all tender offers.Says ‍as of date of offers, aggregate outstanding principal amount of notes was about $2.95 billion​.Says ‍offers are scheduled to expire at 5:00 p.m., New York City Time, on Nov.13, 2017​.  Full Article

Array Biopharma reports initial results from novel immunotherapy combination at SITC annual meeting
Monday, 13 Nov 2017 08:00am EST 

Nov 13 (Reuters) - Array Biopharma Inc :Array biopharma reports initial results from novel immunotherapy combination at the Society For Immunotherapy Of Cancer (SITC) 32nd annual meeting.Array Biopharma Inc - ‍plans to expand ongoing phase 2 CSF1R + PD1 combination study into other tumor types including pancreatic cancer​.  Full Article

Merck receives FDA approval of Prevymis for prevention of CMV infection in allogeneic stem cell transplant patients
Thursday, 9 Nov 2017 06:45am EST 

Nov 9 (Reuters) - Merck & Co Inc :Merck receives FDA approval of Prevymis (letermovir) for prevention of cytomegalovirus (CMV) infection and disease in adult allogeneic stem cell transplant patients.Merck & Co Inc - ‍Prevymis is expected to be available in december​.Merck & Co Inc - ‍list price (wholesaler acquisition cost) per day for Prevymis tablets is $195.00 and for Prevymis injection is $270.00​.  Full Article

Merck & Co updates on investigation of co's Italian unit
Tuesday, 7 Nov 2017 05:01pm EST 

Nov 7 (Reuters) - Merck & Co Inc :Merck & Co Inc says in July 2017, co learned that the prosecution office of Milan, Italy is investigating certain interactions - SEC filing.Merck & Co says the interactions were between co’s Italian subsidiary, certain employees of the subsidiary and certain Italian healthcare providers.Merck says it understands that this is part of a larger investigation involving engagements between various healthcare companies and certain healthcare providers.Merck & Co says it is cooperating with the investigation.  Full Article

BRIEF-Inge Thulin To Join Merck Board Of Directors Effective March 1

* MERCK & CO INC - ‍WITH ADDITION OF THULIN, MERCK BOARD WILL INCLUDE 14 MEMBERS​